Catalyst Dossier · compiled by CeliA 🧫

Ocugen, Inc. (OCGN)

Biological Products, (No Diagnostic Substances) · market cap $420M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-07

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-07Earningsimp 5/10
2026-09-28 (est.)Phase 3 · OCU410STimp 9/10
2027-03-15 (est.)Phase 2 · OCU400 Low Doseimp 7/10

Pipeline

Asset	Phase	Indication
Brimonidine Tartrate	Phase 3	Dry Eye
OCU400 Low Dose	Phase 2	Retinitis Pigmentosa
Brimonidine	Phase 2	Dry Eye
OCU410ST	Phase 3	Stargardt Disease

Price & technical context

3-month

-15.6%

6-month

+10.2%

12-month

+63.4%

52-wk range

$0.93–$2.48

vs 50-day MA

+5.5%

vs 200-day MA

-2.5%

Realized vol

80.2%

Max drawdown

-73.5%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for OCGN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.